An International, Multi Centre, Prospective, Observational Study of Safety, Tolerability and Adherence of Patients With Relapsing Remitting Multiple Sclerosis Administered Interferon Beta-1a (Rebif New Formulation) in Real Life Settings.

Trial Profile

An International, Multi Centre, Prospective, Observational Study of Safety, Tolerability and Adherence of Patients With Relapsing Remitting Multiple Sclerosis Administered Interferon Beta-1a (Rebif New Formulation) in Real Life Settings.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Sep 2014

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms STAR
  • Sponsors Merck KGaA
  • Most Recent Events

    • 05 May 2014 Results published in the Clinical Therapeutics.
    • 06 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Oct 2011 Actual end date (June 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top